MX359011B - Uso de activadores del receptor de acetil-colina nicotínico alfa-7. - Google Patents

Uso de activadores del receptor de acetil-colina nicotínico alfa-7.

Info

Publication number
MX359011B
MX359011B MX2012003413A MX2012003413A MX359011B MX 359011 B MX359011 B MX 359011B MX 2012003413 A MX2012003413 A MX 2012003413A MX 2012003413 A MX2012003413 A MX 2012003413A MX 359011 B MX359011 B MX 359011B
Authority
MX
Mexico
Prior art keywords
activators
acetylcholine receptor
nicotinic acetylcholine
receptor alpha
parkinson
Prior art date
Application number
MX2012003413A
Other languages
English (en)
Spanish (es)
Other versions
MX2012003413A (es
Inventor
Gomez-Mancilla Baltazar
Feuerbach Dominik
Johns Donald
Di Paolo Thérèse
Original Assignee
Novartis Ag Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42990156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX359011(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag Star filed Critical Novartis Ag Star
Publication of MX2012003413A publication Critical patent/MX2012003413A/es
Publication of MX359011B publication Critical patent/MX359011B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2012003413A 2009-09-22 2010-09-22 Uso de activadores del receptor de acetil-colina nicotínico alfa-7. MX359011B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24465809P 2009-09-22 2009-09-22
PCT/EP2010/063946 WO2011036167A1 (en) 2009-09-22 2010-09-22 Use of nicotinic acetylcholine receptor alpha 7 activators

Publications (2)

Publication Number Publication Date
MX2012003413A MX2012003413A (es) 2012-04-30
MX359011B true MX359011B (es) 2018-09-12

Family

ID=42990156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003413A MX359011B (es) 2009-09-22 2010-09-22 Uso de activadores del receptor de acetil-colina nicotínico alfa-7.

Country Status (21)

Country Link
US (3) US10537539B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP2480228B1 (US20070167479A1-20070719-C00034.png)
JP (2) JP6178074B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR20120068878A (US20070167479A1-20070719-C00034.png)
CN (2) CN102573830A (US20070167479A1-20070719-C00034.png)
AU (1) AU2010299967B2 (US20070167479A1-20070719-C00034.png)
BR (1) BR112012006346A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA2774801C (US20070167479A1-20070719-C00034.png)
CL (1) CL2012000702A1 (US20070167479A1-20070719-C00034.png)
EA (1) EA036742B1 (US20070167479A1-20070719-C00034.png)
ES (1) ES2614930T3 (US20070167479A1-20070719-C00034.png)
IL (1) IL218299A (US20070167479A1-20070719-C00034.png)
JO (1) JO3250B1 (US20070167479A1-20070719-C00034.png)
MA (1) MA33590B1 (US20070167479A1-20070719-C00034.png)
MX (1) MX359011B (US20070167479A1-20070719-C00034.png)
NZ (1) NZ598316A (US20070167479A1-20070719-C00034.png)
SG (1) SG178832A1 (US20070167479A1-20070719-C00034.png)
TN (1) TN2012000082A1 (US20070167479A1-20070719-C00034.png)
TW (1) TWI558398B (US20070167479A1-20070719-C00034.png)
WO (1) WO2011036167A1 (US20070167479A1-20070719-C00034.png)
ZA (1) ZA201201066B (US20070167479A1-20070719-C00034.png)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TWI558398B (zh) * 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
BR112013018726A2 (pt) * 2011-01-27 2016-10-25 Novartis Ag uso de ativadores de alfa 7 do receptor nicotínico de acetilcolina
CN103443092B (zh) 2011-02-03 2015-11-25 鲁平有限公司 用作α7胆碱受体调节剂的吡咯衍生物
CU24177B1 (es) 2011-02-23 2016-04-25 Lupin Ltd Derivados de heteroarilo como moduladores de nachr alfa 7
BR112013023813A2 (pt) * 2011-03-18 2016-12-13 Novartis Ag combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson
JP2014509641A (ja) 2011-03-31 2014-04-21 ルピン・リミテッド アルツハイマー病やパーキンソン病などの神経変性疾患の治療に用いられるニコチン性アセチルコリン受容体モジュレータとしてのピロール誘導体
WO2013005153A1 (en) 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
CA2852268C (en) * 2011-10-20 2020-08-25 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
EP2822946A1 (en) 2012-03-06 2015-01-14 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
MY174339A (en) * 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
EP2945936A1 (en) 2012-11-12 2015-11-25 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
WO2014111837A1 (en) * 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
KR101879920B1 (ko) * 2013-01-15 2018-07-18 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
WO2014111839A1 (en) 2013-01-16 2014-07-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
CA2892682A1 (en) 2013-03-13 2014-09-18 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
EA030631B1 (ru) 2013-07-31 2018-09-28 Новартис Аг 1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом
WO2015168616A1 (en) * 2014-05-02 2015-11-05 Abbvie Inc. Neuronal nicotinic agonists and methods of use
WO2016040517A1 (en) 2014-09-09 2016-03-17 Merial Inc. Mammalian cell lines expressing functional nematode acetylcholine receptors and use thereof for high-throughput screening assays
JP6612874B2 (ja) 2014-12-16 2019-11-27 アクソファント サイエンシーズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物
CA2988968A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
US20170247393A1 (en) * 2015-10-20 2017-08-31 Forum Pharmaceuticals, Inc. Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors
KR102636383B1 (ko) 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
JP2022521467A (ja) 2019-02-05 2022-04-08 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US5990168A (en) 1996-04-18 1999-11-23 Alberta Cancer Board Methods and compositions for the treatment of ataxia telangiectasia
US7214686B2 (en) * 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6908631B1 (en) * 1997-12-01 2005-06-21 Nicogen, Inc. Therapeutic and diagnostic methods dependent on CYP2A enzymes
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
DE69930552T2 (de) 1998-12-16 2006-11-30 University Of South Florida, Tampa Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
FR2804430B1 (fr) 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
US20050245567A1 (en) 2002-08-14 2005-11-03 Dan Peters Novel quinuclidine derivatives and their use
EP1531820A1 (en) 2002-08-30 2005-05-25 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
CA2515948A1 (en) 2003-02-14 2004-09-02 Memory Pharmaceuticals Corporation Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof
NZ540998A (en) 2003-02-27 2008-06-30 Neurosearch As Novel diazabicyclic aryl derivatives
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
WO2005044267A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
EP1677788A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes iii
CA2549967A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
DE602004010299T2 (de) 2003-12-22 2008-09-18 Memory Pharmaceuticals Corp. Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
BRPI0506890A (pt) 2004-02-04 2007-07-17 Neurosearch As derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo
CN100432075C (zh) 2004-02-04 2008-11-12 神经研究公司 作为烟碱样乙酰胆碱受体配体的二氮杂双环芳基衍生物
WO2005079802A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
AU2005227324A1 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
EP1742944B1 (en) 2004-04-22 2010-11-10 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
NZ551712A (en) 2004-05-07 2010-07-30 Memory Pharm Corp 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof
EP1751150A2 (en) 2004-05-19 2007-02-14 Neurosearch A/S Novel azabicyclic aryl derivatives
GB0412019D0 (en) 2004-05-28 2004-06-30 Novartis Ag Organic compounds
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1802616B1 (en) 2004-10-15 2011-01-12 NeuroSearch A/S Novel azabicyclic aryl derivatives and their medical use
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2006051407A1 (en) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
WO2006051394A1 (en) * 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
WO2006058879A1 (en) 2004-11-30 2006-06-08 Neurosearch A/S Novel diazabicyclic aryl derivatives as cholinergy ligands
JP2008523058A (ja) 2004-12-10 2008-07-03 アボット・ラボラトリーズ 縮合ビシクロ複素環置換キヌクリジン誘導体
AU2005319248A1 (en) 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US20060142349A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
JP2008530172A (ja) 2005-02-16 2008-08-07 ノイロサーチ アクティーゼルスカブ ジアザ二環系アリール誘導体及びそれらのニコチン様アセチルコリン受容体におけるコリン作動性リガンドとしての使用
CA2602348C (en) 2005-03-31 2011-03-01 Pfizer Products Inc. Cyclopentapyridine and tetrahydroquinoline derivatives
US7585629B2 (en) 2005-04-22 2009-09-08 Cedars-Sinai Medical Center Compositions and methods for spinocerebellar ataxia
FR2884822B1 (fr) 2005-04-22 2007-06-29 Aventis Pharma Sa Derives de triazines, leur preparation et leur application en therapeutique
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
US8629163B2 (en) 2007-10-31 2014-01-14 University Of Kentucky Research Foundation Tetrakis-quaternary ammonium salts and methods for modulating neuronal nicotinic acteylcholine receptors
SG165417A1 (en) 2005-09-23 2010-10-28 Memory Pharm Corp Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
BRPI0619672A2 (pt) 2005-11-09 2011-10-11 Memory Pharm Corp composto, composição farmacêutica, e, uso de um composto
ATE473978T1 (de) 2005-12-06 2010-07-15 Neurosearch As Neue diazabicyclische arylderivate und medizinische verwendung dafür
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
CA2627630A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
US7662965B2 (en) 2006-01-26 2010-02-16 Cornerstone Therapeutics, Inc. Anabaseine derivatives, pharmaceutical compositions and method of use thereof
WO2007085036A1 (en) 2006-01-26 2007-08-02 Medizinische Universität Wien Treatment of friedreich' s ataxia
AU2007216531A1 (en) 2006-02-14 2007-08-23 Neurosearch A/S Novel diazabicycloalkane derivatives and their medical use
CA2637531A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
UA95099C2 (ru) 2006-02-22 2011-07-11 Арнольд Мунних Применение деферипрона при лечении железо-индуцированного повреждения митохондрий, который является следствием атаксии фридрейха
KR20090005305A (ko) 2006-03-27 2009-01-13 화이자 프로덕츠 인크. 바레니클린 표준물질 및 불순물 제어
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
JP2009537599A (ja) 2006-05-23 2009-10-29 ノイロサーチ アクティーゼルスカブ 新規８，１０−ジアザ−ビシクロ［４．３．１］デカン誘導体及びそれらの医学的使用
DE602007005255D1 (de) 2006-05-23 2010-04-22 Neurosearch As Neuartige 1,4-diazabicycloä3.2.2ünonan-derivate und deren medizinische verwendung
MX2008014887A (es) 2006-05-30 2008-12-05 Neurosearch As Nuevos derivados de 1,4-diaza-biciclo[3.2.2]nonil oxadiazolilo y su uso medico.
AU2007267176A1 (en) 2006-05-30 2007-12-06 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use
WO2007146066A2 (en) 2006-06-06 2007-12-21 Critical Therapeutics, Inc. Novel piperazines, pharmaceutical compositions and methods of use thereof
WO2007149163A2 (en) 2006-06-16 2007-12-27 University Of Kentucky Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
CA2657640A1 (en) 2006-07-14 2008-01-24 Pfizer Products Inc. Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
MX2009008324A (es) 2007-02-16 2009-10-20 Memory Pharm Corp Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
GB2448224B (en) * 2007-04-02 2010-09-01 Parkinson S Inst Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
JP2010528037A (ja) 2007-05-24 2010-08-19 メモリー・ファーマシューティカルズ・コーポレイション ５−ｈｔ６受容体親和性を有する４’置換化合物
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US20090069337A1 (en) 2007-08-15 2009-03-12 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-ht6 receptor affinity
US8114891B2 (en) 2007-10-01 2012-02-14 Comentis, Inc. 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof
JP5362729B2 (ja) 2007-10-04 2013-12-11 エフ．ホフマン−ラ ロシュ アーゲー シクロプロピルアリールアミド誘導体及びその使用
CA2701214C (en) 2007-10-04 2016-08-02 F. Hoffmann-La Roche Ag Tetrazole-substituted aryl amide derivatives and uses thereof
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
CA2714232A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
ES2757648T3 (es) 2008-02-19 2020-04-29 Myocept Inc Agentes de quimiodenervación dirigida postsinápticamente y sus procedimientos de uso
US9463190B2 (en) 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
ES2392795T3 (es) 2008-04-17 2012-12-13 Proximagen Limited Indoles como moduladores del receptor nicotínico de acetilcolina de subtipo alfa-7
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2009143019A2 (en) 2008-05-23 2009-11-26 University Of South Florida Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity
US20100016297A1 (en) 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100056491A1 (en) 2008-08-29 2010-03-04 Memory Pharmaceuticals Corporation 4'-amino cyclic compounds having 5-ht6 receptor affinity
MX2011003429A (es) 2008-10-13 2011-05-02 Hoffmann La Roche Metodo libre de diazonio para fabricar un compuesto intermedio de indazol en la sintesis de las amidas del acido 5-(trifluorometoxi)-1h-3-indazolcarboxilico biciclico.
WO2010056622A1 (en) 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102802630A (zh) 2009-06-17 2012-11-28 塔加西普特公司 通过神经元烟碱受体配体逆转左旋多巴诱导的运动障碍
EP2456438A2 (en) 2009-07-23 2012-05-30 Novartis AG Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
TWI558398B (zh) * 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途

Also Published As

Publication number Publication date
IL218299A (en) 2017-02-28
ES2614930T3 (es) 2017-06-02
ZA201201066B (en) 2012-10-31
TW201116534A (en) 2011-05-16
US20210338621A1 (en) 2021-11-04
CL2012000702A1 (es) 2012-09-14
IL218299A0 (en) 2012-04-30
SG178832A1 (en) 2012-04-27
TWI558398B (zh) 2016-11-21
JP2013505282A (ja) 2013-02-14
TN2012000082A1 (en) 2013-09-19
AU2010299967A1 (en) 2012-03-08
AU2010299967B2 (en) 2014-03-13
EP2480228A1 (en) 2012-08-01
JP2016104743A (ja) 2016-06-09
US10537539B2 (en) 2020-01-21
US20120172346A1 (en) 2012-07-05
CA2774801C (en) 2017-11-28
US11096916B2 (en) 2021-08-24
CN110051670A (zh) 2019-07-26
EA036742B1 (ru) 2020-12-15
CN102573830A (zh) 2012-07-11
MA33590B1 (fr) 2012-09-01
CA2774801A1 (en) 2011-03-31
EP2480228B1 (en) 2016-11-16
NZ598316A (en) 2013-11-29
BR112012006346A2 (pt) 2017-05-23
WO2011036167A1 (en) 2011-03-31
KR20120068878A (ko) 2012-06-27
JP6178074B2 (ja) 2017-08-09
MX2012003413A (es) 2012-04-30
US20200108035A1 (en) 2020-04-09
EA201200507A1 (ru) 2012-10-30
JO3250B1 (ar) 2018-09-16

Similar Documents

Publication Publication Date Title
TN2012000082A1 (en) Use of nicotinic acetylcholine receptor alpha 7 activators
HUE043807T2 (hu) GLYX Alzheimer-kór, Parkinson-kór vagy Huntington-kór kezelésében történõ alkalmazásra
HK1220631A1 (zh) 用於遞送治療劑的陰離子核心組合物以及製備和使用所述組合物的方法
EP2308493A4 (en) ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
IN2012DN01261A (US20070167479A1-20070719-C00034.png)
MX2009009415A (es) Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.
PL2401263T3 (pl) Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
JO2730B1 (en) Medications for the treatment of endometriosis
EP2139469A4 (en) COBALAMINTAXAN bioconjugates
CL2008000091A1 (es) Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria.
MX2015009153A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
EP2517698A4 (en) ACTIVE AGENT FOR THE TREATMENT OF MORBUS PARKINSON
UA96574C2 (ru) Использование ивабрадина для получения лекарств, предназначенных для лечения эндотелиальной дисфункции
MX2009007054A (es) Uso terapeutico novedoso para tratar leucemia.
EP2039342A4 (en) MEANS FOR MAINTAINING THE HARDENING TISSUE STRUCTURE
GB0716609D0 (en) Sweat rate sensor
TH129185B (th) การใช้ของสารก่อกระตุ้นนิโคทินิค อะซิทิลโคลีน รีเซปเตอร์ อัลฟา 7 (Use of nicotinic acetylcholine receptor alpha 7 activators)
EP2496080A4 (en) METHOD FOR THE TREATMENT OF MORBUS PARKINSON
TH129185A (th) การใช้ของสารก่อกระตุ้นนิโคทินิค อะซิทิลโคลีน รีเซปเตอร์ อัลฟา 7 (Use of nicotinic acetylcholine receptor alpha 7 activators)
HU0700083D0 (en) Chair facilitatingtposer action, sex apparatus
DE202006016952U1 (de) Passformverstellbares Umstandskleid
UA36331U (ru) Применение рисперидона как средства для лечения опиоидной зависимости
UA40770U (ru) Применение антагониста рецепторов интерлейкина-1 в качестве кардиопротекторного средства

Legal Events

Date Code Title Description
FG Grant or registration